METHOD OF REPAIRING TISSUE OF A MAMMAL

• US 20070098704A1
• Filed: 11/30/2006
• Published: 05/03/2007
• Est. Priority Date: 02/28/2005
• Status: Abandoned Application

• Current Assignee: Donnie Rudd
• Original Assignee: Donnie Rudd
• Inventors: RUDD, Donnie
• Application Number:
  US11/565,045
• Publication Number:
  US 20070098704A1
• Time in Patent Office: Days
• US Class Current: 424/93.21
• CPC Class Codes: A01N 1/02 Preservation of living parts
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/197 the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid carnitine A61K31/205
• CPC Class Codes: A61K 33/34 Copper; Compounds thereof
• CPC Class Codes: A61K 35/28 Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• CPC Class Codes: A61K 38/193 Colony stimulating factors [CSF]
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 1/18 for pancreatic disorders, e.g. pancreatic enzymes
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 19/00 Drugs for skeletal disorders
• CPC Class Codes: A61P 21/00 Drugs for disorders of the muscular or neuromuscular system
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 31/10 Antimycotics
• CPC Class Codes: A61P 33/02 Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
• CPC Class Codes: A61P 33/06 Antimalarials
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/02 : specific for leukemia
• CPC Class Codes: A61P 37/02 : Immunomodulators
• CPC Class Codes: A61P 37/06 : Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 7/00 : Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: A61P 7/04 : Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
• CPC Class Codes: A61P 7/06 : Antianaemics
• CPC Class Codes: A61P 9/00 : Drugs for disorders of the cardiovascular system
• CPC Class Codes: C12N 2501/125 : Stem cell factor [SCF], c-kit ligand [KL]
• CPC Class Codes: C12N 2501/22 : Colony stimulating factors (G-CSF, GM-CSF)
• CPC Class Codes: C12N 5/0647 : Haematopoietic stem cells; Uncommitted or multipotent progenitors
• CPC Class Codes: Y02A 50/30 : Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Method of treating disease or repairing tissue with compositions comprising mammalian peripheral blood stem cells, preferably CD34+/CD38− cells, and preferably peripheral blood stem cells resulting from TVEMF-expansion.

Claims

1. A method of repairing tissue of a mammal comprising:

administering to the mammal a therapeutically effective amount of a composition comprising peripheral blood stem cells, wherein the peripheral blood stem cells are in a number per volume that is at least seven times greater than in naturally-occurring peripheral blood and wherein the peripheral blood stem cells have a three dimensional geometry and cell-to-cell support and cell-to-cell geometry that is essentially the same as stem cells of naturally-occurring peripheral blood.

2. The method of claim 1 wherein the composition further comprises a pharmaceutically acceptable carrier.

3. A method of repairing tissue of a mammal comprising:

administering to the mammal a therapeutically effective amount of a composition comprising TVEMF-expanded peripheral blood stem cells that are TVEMF-expanded and a pharmaceutically acceptable carrier.

4. The method of claim 3, wherein the tissue to be repaired is human tissue.

5. The method of claim 4, wherein the mammal is the source of the peripheral blood stem cells prior to TVEMF-expansion.

6. The method of claim 4, wherein the tissue to be repaired is at least one selected from the group consisting of liver tissue, heart tissue, hematopoietic tissue, blood vessels, skin tissue, muscle tissue, gut tissue, pancreatic tissue, central nervous system cells, bone, cartilage tissue, connective tissue, pulmonary tissue, spleen tissue and brain tissue.

7. The method of claim 3, wherein the amount of TVEMF-expanded peripheral blood stem cells to be administered to the mammal is at least 20 ml of a composition having 10⁷ to 10⁹ stem cells/ml.

8. A method of treating a disease of a mammal comprising the step of administering to the mammal a therapeutically effective amount of a composition comprising the peripheral blood stem cells, wherein the peripheral blood stem cells are in a number per volume that is at least seven times greater than in naturally-occurring peripheral blood and wherein the peripheral blood stem cells have a three-dimensional geometry and cell-to-cell support and cell-to-cell geometry that is essentially the same as stem cells of naturally-occurring peripheral blood.

9. The method of claim 8 wherein the composition further comprises a pharmaceutically acceptable carrier.

10. A method of treating a disease of a mammal comprising the step of administering to the mammal a therapeutically effective amount of a composition comprising peripheral blood stem cells and a pharmaceutically acceptable carrier, wherein the peripheral blood stem cells have been TVEMF-expanded.

11. The method of claim 10, wherein the mammal is a human and wherein the mammal is the source of the peripheral blood stem cells prior to TVEMF-expansion.

12. The method of claim 11, wherein the amount of TVEMF-expanded peripheral blood stem cells to be administered to the mammal is at least 20 ml of a composition having 10⁷ to 10⁹ stem cells/ml.

13. The method of claim 11, wherein the disease is selected from at least one of the group consisting of diseases resulting from a failure or dysfunction of normal blood cell production and maturation, hyperproliferative stem cell disorders, aplastic anemia, pancytopenia, thrombocytopenia, red cell aplasia, Blackfan-Diamond syndrome due to drugs, radiation, or infection, idiopathic;

hematopoietic malignancies, acute lymphoblastic (lymphocytic) leukemia, chronic lymphocytic leukemia, acute myelogenous leukemia, chronic myelogenous leukemia, acute malignant myelosclerosis, multiple myeloma, polycythemia vera, agnogenic myelometaplasia, Waldenstrom'"'"'s macroglobulinemia, Hodgkin'"'"'s lymphoma, non-Hodgkins'"'"'s lymphoma;

immunosuppression in patients with malignant, solid tumors, malignant melanoma, carcinoma of the stomach, ovarian carcinoma, breast carcinoma, small cell lung, carcinoma, retinoblastoma, testicular carcinoma, glioblastoma, rhabdomyosarcoma, neuroblastoma, Ewing'"'"'s sarcoma, lymphoma;

auto immune diseases, rheumatoid arthritis, diabetes type I, chronic hepatitis, multiple sclerosis, and systemic lupus erythematosus;

genetic (congenital) disorders, anemias, familial aplastic, Fanconi'"'"'s syndrome, Bloom'"'"'s syndrome, pure red cell aplasia (PRCA), dyskeratosis congenital, Blackfan-Diamond syndrome, congenital dyserythropoietic syndromes I-IV, Chwachmann-Diamond syndrome, dihydrofolate reductase deficiencies, form amino transferase deficiency, Lesch-Nyhan syndrome, congenital spherocytosis, congenital elliptocytosis, congenital stomatocytosis, congenital Rh null disease, paroxysmal nocturnal hemoglobinuria, G6PD (glucose-6-phosphate dehydrogenase), variants 1,2,3, pyruvate kinase deficiency, congenital erythropoietin sensitivity, deficiency, sickle cell disease and trait, thalassemia alpha, beta, gamma met-hemoglobinemia, congenital disorders of immunity, severe combined immunodeficiency disease, (SCID), bare lymphocyte syndrome, ionophore-responsive combined, immunodeficiency, combined immunodeficiency with a capping abnormality, nucleoside phosphorylase deficiency, granulocyte actin deficiency, infantile agranulocytosis, Gaucher'"'"'s disease, adenosine deaminase deficiency, Kostmann'"'"'s syndrome, reticular dysgenesis, congenital leukocyte dysfunction syndromes;

osteopetrosis, myelosclerosis, acquired hemolytic anemias, acquired immunodeficiencies, infectious disorders causing primary or secondary immunodeficiencies, bacterial infections (e.g., Brucellosis, Listerosis, tuberculosis, leprosy), parasitic infections (e.g., malaria, Leishmaniasis), fungal infections, disorders involving disproportions in lymphoid cell sets and impaired immune functions due to aging phagocyte disorders, Kostmann'"'"'s agranulocytosis, chronic granulomatous disease, Chediak-Higachi syndrome, neutrophil actin deficiency, neutrophil membrane GP-180 deficiency, metabolic storage diseases, mucopolysaccharidoses, mucolipidoses, miscellaneous disorders involving immune mechanisms, Wiskott-Aldrich Syndrome, and alpha 1-antitrypsin deficiency.